NCT00650338

Brief Summary

To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
165

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Mar 2008

Shorter than P25 for phase_2

Geographic Reach
1 country

14 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2008

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

March 27, 2008

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 1, 2008

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2008

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2008

Completed
Last Updated

November 3, 2011

Status Verified

November 1, 2011

Enrollment Period

6 months

First QC Date

March 27, 2008

Last Update Submit

November 1, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • To investigate the dose-response relationship of DE-104 in lowering intraocular pressure (IOP)

    28 days

Secondary Outcomes (1)

  • To compare the safety and efficacy of DE-104 ophthalmic solution with placebo and 0.005% latanoprost.

    35 days

Study Arms (5)

1

EXPERIMENTAL

\<described in intervention\>

Drug: DE-104 ophthalmic solution, low concentration

2

EXPERIMENTAL

\<described in intervention\>

Drug: DE-104 ophthalmic solution, medium concentration

3

EXPERIMENTAL

\<described in intervention\>

Drug: DE-104 ophthalmic solution, high concentration

4

PLACEBO COMPARATOR

\<described in intervention\>

Drug: Placebo

5

ACTIVE COMPARATOR

\<described intervention\>

Drug: 0.005% latanoprost

Interventions

Topical ocular application

1

Topical ocular application

3

placebo

4

Topical ocular application

5

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Provided signed, written informed consent.
  • Diagnosed with primary open-angle glaucoma or ocular hypertension.
  • years of age and older.
  • If a subject is a female of childbearing potential, she must utilize reliable contraceptive throughout the study, and must have a negative urine pregnancy test prior to enrollment into this study.

You may not qualify if:

  • Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.
  • Presence of any abnormality or significant illness that could be expected to interfere with the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (14)

Sall Research Medical Center

Artesia, California, 90701, United States

Location

USC Department of Ophthalmology

Los Angeles, California, 90033, United States

Location

Wolstan Eye Associates

Torrance, California, 90505, United States

Location

East Florida Eye Institute

Stuart, Florida, 34994, United States

Location

Seidenberg Protzko Eye Associates

Bel Air, Maryland, 21014, United States

Location

University of Nebraska Medical Center

Omaha, Nebraska, 68198-5540, United States

Location

Rochester Ophthalmological Group, PC

Rochester, New York, 14618, United States

Location

Cornerstone Eye Care

High Point, North Carolina, 27262, United States

Location

Associated Glaucoma Consultants

Philadelphia, Pennsylvania, 19107, United States

Location

Keystone Research, Ltd.

Austin, Texas, 78731, United States

Location

David Shulman, MD P-A

San Antonio, Texas, 78209, United States

Location

Eye Clinics of South Texas

San Antonio, Texas, 78209, United States

Location

Medical Center Ophthalmology Associates

San Antonio, Texas, 78240, United States

Location

Virginia Eye Consultants

Norfolk, Virginia, 23507, United States

Location

MeSH Terms

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

Latanoprost

Condition Hierarchy (Ancestors)

GlaucomaEye Diseases

Intervention Hierarchy (Ancestors)

Prostaglandins F, SyntheticProstaglandins, SyntheticProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological Factors

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 27, 2008

First Posted

April 1, 2008

Study Start

March 1, 2008

Primary Completion

September 1, 2008

Study Completion

October 1, 2008

Last Updated

November 3, 2011

Record last verified: 2011-11

Locations